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Abstract
Background: Cats with feline calicivirus (FCV)-related symptoms are commonly presented to veterinary practitioners.
Various clinical manifestations have been attributed to FCV, i.e. upper respiratory tract disease (URTD), oral ulcerations,
gingivostomatitis, limping syndrome and virulent systemic disease. Additionally, healthy cats can shed FCV. The aims of
this study were 1) to investigate the frequency of FCV in cats with FCV-related symptoms and in healthy cats in
Switzerland, 2) to assess risk and protective factors for infection, such as signalment, housing conditions, vaccination,
and co-infection with URTD-associated pathogens, and 3) to address the association between clinical symptoms and
FCV infection.
Results: Oropharyngeal, nasal and conjunctival swabs were collected in 24 veterinary practices from 200 FCV-suspect
and 100 healthy cats originating from 19 cantons of Switzerland. The samples were tested for FCV using virus isolation
and reverse-transcription real-time quantitative polymerase chain reaction (qPCR) and for feline herpesvirus-1 (FHV-1),
Mycoplasma felis, Chlamydophila felis, Bordetella bronchiseptica using real-time qPCR. Within the two populations (FCV-
suspect/healthy), the observed PCR prevalences were: FCV 45 %/8 %, FHV-1 20 %/9 %, C. felis 8 %/1 %, B. bronchiseptica
4 %/2 %, M. felis 47 %/31 % and any co-infections thereof 40 %/14 %. Based on multivariable regression models
amongst FCV-suspect cats (odds ratio [95 % confidence interval]), co-infection with M. felis (1.75 [0.97; 3.14]), group
housing (2.11 [1.02; 4.34]) and intact reproductive status (1.80 [0.99; 3.28]) were found to be risk factors for FCV
infection. In healthy cats, intact reproductive status (22.2 [1.85; 266.7]) and group housing (46.4 [5.70; 377.7]) were found
to be associated with FCV infection. Based on an univariable approach, FCV-suspect cats were found to be significantly
less often FCV-positive when vaccinated (0.48 [0.24; 0.94]). Oral ulcerations, salivation, gingivitis and stomatitis, but not
classical signs of URTD were significantly associated with FCV infection (all p < 0.001).
Conclusions: FCV was detected in less than half of the cats that were judged FCV-suspect by veterinary practitioners.
For a clinical diagnosis, FCV-related symptoms should be revisited. FCV infection was present in some healthy cats,
underlining the importance of asymptomatic carriers in FCV epidemiology. To reduce FCV-related problems in multi-
cat environments, reduction of group size in addition to the generally recommended vaccination are advocated.
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Background
Feline calicivirus (FCV) is a RNA virus that occurs
worldwide in domestic cats and exotic felids [1, 2]. FCV
infections are commonly associated with oral ulcerations
and salivation [3, 4]. Other clinical syndromes that have
been attributed to FCV infection include chronic stoma-
titis [3, 5] and a limping syndrome [6–8]. Some years
ago, highly virulent systemic FCV infections associated
with fatal disease have been reported in several coun-
tries, initially in North America [9, 10] and subsequently
in Europe [11–13]. Outbreaks of severe FCV infections
associated with edema and skin ulcerations have also
been described in cats in Switzerland (Willi et al., sub-
mitted for publication).
FCV has also been assigned to the upper respiratory
tract disease (URTD) complex (‘cat flu’) [14–17]. In
addition to FCV, at least four other pathogens have
been shown to be associated with this syndrome,
including feline herpesvirus type 1 (FHV-1), Mycoplasma
felis, Chlamydophila felis and Bordetella bronchiseptica
[14, 16, 18–24]. Cats with URTD are commonly presented
to veterinary practitioners and show symptoms such as
lethargy, pyrexia, anorexia, sneezing, nasal discharge, ocu-
lar discharge, conjunctivitis and keratitis [14, 19].
Conventional, nested and real-time reverse-transcriptase
quantitative polymerase chain reaction (RT-qPCR) assays
have been developed to amplify FCV-specific RNA from
clinical specimens [25–29]. The high genetic variability of
FCV can hamper the diagnostic sensitivity of FCV-specific
molecular assays [2]. Virus isolation has been advocated
as an alternative diagnostic tool, but this method is not
routinely available [2]. Virus isolation is less sensitive to
genomic variation, but the method might fail due to virus
inactivation during transport, thus resulting in reduced
diagnostic sensitivity [2].
FCV vaccines have been shown to be efficacious in pro-
tecting cats from the development of severe disease; how-
ever, they do not induce sterilizing immunity [30, 31].
Moreover, most commercially available vaccines have been
based on only a few FCV strains (i.e. FCV F9 and 255) for
many decades. Therefore, the protective potential of FCV
vaccines against different circulating FCV isolates has
been controversially discussed in recent years [32–35]. Ef-
forts are made for the identification of new vaccine strains
with broader cross-reactivity, the development of bi- or
polyvalent vaccines and the inclusion of local FCV isolates
[35–38]. Along these lines, a vaccine containing two novel
FCV strains has become commercially available in
Switzerland (FCV G1 and 431) [35, 36].
Despite the introduction of FCV vaccines several de-
cades ago, cats with FCV-related symptoms are still
commonly presented in veterinary practices. A presump-
tive clinical diagnosis relies on the presence of FCV-
related symptoms [2]. However, clinical signs induced by
FCV and other URTD-associated pathogens can overlap
and co-infections are common [4, 14–17]. Molecular as-
says to detect URTD-associated pathogens in clinical
specimens might aid the diagnosis. Because asymp-
tomatic carriers have been reported, results of mo-
lecular assays must be interpreted together with clinical
presentation.
The aims of this study were to investigate the fre-
quency of FCV in cats suspected FCV infected by veter-
inary practitioners and in clinically healthy cats in
Switzerland, and to address potential risk and protective
factors for infection in both groups of cats, such as
signalment, housing conditions, vaccination, and co-
infection with URTD-associated pathogens. Further-
more, the association between a number of different
clinical symptoms and FCV infection was assessed.
Methods
Cats
A total of 200 clinically diseased cats with symptoms
compatible with FCV infection (FCV-suspect cats) and
100 clinically healthy cats were enrolled. The study was
part of a large FCV project with the goal to obtain a col-
lection of FCV isolates from symptomatic and asymp-
tomatic cats in Switzerland for genetic and serological
studies. Both populations were sampled by veterinary
surgeons in Switzerland between September 2012 and
April 2013. The goal was to include samples originating
from 20 randomly selected veterinary practices in 17 dif-
ferent geographic regions (cantons) of Switzerland (ten
FCV-suspect and five healthy cats per practice). Only
one cat per owner (e.g., same household, cattery) was in-
cluded. The veterinarians obtained informed consent
from the cat owners. All samples were taken as part of a
diagnostic workup or for routine testing of FeLV/FIV in
healthy cats and all results were provided to the veteri-
narians and the cat owners; no ethical approval was
necessary for this study in compliance with Swiss regula-
tions [39]. Veterinary practices that were not able to col-
lect a sufficient number of samples within the given
time frame (eight months) were supported by a second
or third veterinary practice within the same canton. This
resulted in the participation of 24 veterinary practices in
17 cantons and the enrollment of 300 cats originating
from 19 out of 26 cantons in Switzerland (Fig. 1).
The participating veterinarians were provided with a
list of the following FCV-related clinical signs: sneezing,
nasal and/or ocular discharge, conjunctivitis, caudal sto-
matitis, chronic stomatitis and/or gingivitis, lingual and/
or oral ulceration, pneumonia, shifting lameness, or a
combination of fever, cutaneous edema and dermal ul-
ceration of the face and/or limbs. The clinical signs were
selected based on the guidelines on feline calicivirus in-
fection by the European Advisory Board on Cat Diseases
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(ABCD) and a recent publication [2, 40]. The written in-
structions contained illustrations on how to recognize
FCV-associated clinical signs, as described above, and
how to collect and ship the samples. Inclusion criteria
for clinically healthy cats were the absence of any clinical
signs based on anamnesis and clinical examination of
the participating veterinarian. Cats that had been vacci-
nated against FCV, FHV-1 or C. felis within 21 days
prior to the sample collection or that were younger than
eight weeks were excluded.
To record demographic data for each enrolled animal,
the veterinarians filled out a questionnaire during the
cat’s visit at the clinic. To avoid interviewer bias, the
participating veterinarians received written instructions
on how to fill in the questionnaire. A similar question-
naire has been used in earlier studies [41, 42]. The ques-
tionnaire was comprised of different sections on
geographic data (address of the cat owner), demographic
data (age, sex, reproductive status, breed of the cat), hus-
bandry data (type of husbandry, such as private home,
farm, cat breeder, feral cat and cattery, number of cats
per household, outdoor access, contact to dogs with
kennel cough), data on vaccine history according to the
clinical record and vaccination card (vaccination status
for FCV/FHV-1/feline parvovirus, date of primary immu-
nization, booster immunizations, vaccines used, vaccination
Fig. 1 Map of Switzerland depicting the origin of the 300 cats enrolled in the study. The numbers listed give the number of cats per canton:
a FCV-suspect/healthy cats; b FCV-positive/all cats. Basel-Landschaft and Basel-Stadt are listed as a single canton. Maps were produced using QGIS [51]
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status for feline leukemia virus (FeLV), date of the last
FeLV vaccination), retrovirus status (FeLV and/or feline
immunodeficiency virus (FIV) test results and date of test-
ing), data on medical history (antiviral, antibiotic and
immunosuppressive treatment at the time of sample col-
lection and up to two months before collection) and re-
sults of the clinical examination.
Sample collection and analysis
An oropharyngeal cytobrush, as well as a nasal and a con-
junctival cotton swab were collected from each cat. Sam-
ple collection material was provided by the investigators.
Conjunctival swabs were collected prior to any diagnostic
treatment, such as fluorescein application. Each cytobrush
and swab was placed in a sterile Safe-Lock Eppendorf tube
containing 300 μL of sterile viral transport medium. The
medium consisted of 200 mL bi-distilled sterile water,
4 mL HEPES-Buffer 1 M (Sigma-Aldrich Chemie GmbH,
Steinheim, Germany), 25 mL Dulbecco’s MEM 10x (Bio-
chrom, Berlin, Germany), 25 mL heat inactivated fetal calf
serum (Charge DO2303P, Origin South America,
Bio Concept, Allschwil, Switzerland), 3 mL 100 ×
Antibiotic-Antimycotic (Gibco, Life Technologies, Lucerne,
Switzerland) and 4 mL sodium hydrogen bicarbonate 7.5 %
(Merck, Darmstadt, Germany) at a pH of 7 that was adjusted
using 1 M sodium hydroxide (Merck). Samples were stored
at 4 °C prior to shipping to the laboratory by priority mail.
All samples were processed within 96 h after collection.
Sample processing and total nucleic acid (TNA) extraction
Upon arrival, the cytobrushes and swabs were incubated
at 40 °C for 10 min. The cytobrushes and swabs were
then turned upside down and centrifuged for 1 min at
6440 × g. The samples from each patient (oropharyngeal
cytobrush and nasal and conjunctival swabs) were
pooled and subsequently divided as follows: two aliquots
of 200 μL were used for TNA extractions and 400 μL
were used for virus isolation. TNA extraction was per-
formed using 200 μL of sample or cell culture super-
natant with the MagNa Pure LC (Roche Diagnostics AG,
Rotkreuz, Switzerland) using the MagNa Pure LC Total
Nucleic Acid Isolation Kit (Roche Diagnostics) following
the manufacturer’s instructions. In each batch of extrac-
tion, a negative control that consisted of 200 μL of PBS
was used to monitor for cross-contamination. TNA was
stored at -20 °C until qPCR analysis.
Virus isolation
For virus isolation, 400 μL of each sample were filtered
(Filtropur S 0.45 μm syringe filter, Sarstedt, Nümbrecht,
Germany), incubated on 80 % confluent Crandell-Rees
feline kidney cells in 24-well plates (TPP Tissue Culture
Testplate 24, TPP Techno Plastic Products AG, Trasadin-
gen, Switzerland) and cultured using RPMI 1640 Medium
(Sigma-Aldrich Chemie GmbH) supplemented with 10 %
heat inactivated fetal calf serum (Invitrogen, Basel,
Switzerland), 2 mM L-Glutamin (Gibco, Life Technologies)
and 1x Antibiotic-Antimycotic (Gibco, Life Technologies).
For each sample culture, a negative medium-only control
was run in parallel. The samples were incubated on cells
for two hours before 300 μL of complete medium were
added. The cells were fed daily and evaluated for the pres-
ence of a cytopathic effect. As soon as a cytopathic effect
became visible or after a maximum of seven days, the su-
pernatants were collected for TNA extraction and for
storage at −80 °C until further use. If the TNA extraction
could not be performed on the day of collection, 300 μL
Lysis Buffer (MagNa Pure LC Total Nucleic Acid Isolation
Kit, Roche Diagnostics) were added to the 200 μL of
supernatant and the mixture was stored at −20 °C as rec-
ommended by the manufacturer. TNA was extracted from
the cell culture supernatants after a maximum of 72 h of
storage.
Real-time qPCR and RT-qPCR assays
All real-time qPCR assays in the current study were run
with 5 μL TNA in an end volume of 25 μL. Positive and
negative controls were run with each RT-qPCR and
qPCR assay. All oligonucleotides were synthetized by
Microsynth AG (Balgach, Switzerland), and all qPCR as-
says were run on an ABI 7500Fast Real-Time PCR sys-
tem (Applied Biosystems, Rotkreuz, Switzerland). For
quantitative analyses, CT values were used.
For FCV, two previously described FCV real-time Taq-
Man RT-qPCR assays were used [25, 26]. The assays
were optimized prior to the start of the experiment. The
FCV RT-qPCR S1 [25] reaction contained 1 x One step
RT-qPCR MasterMix Low ROX (Eurogentec, Seraing,
Belgium), 300 nM forward primer, 900 nM reverse pri-
mer, 250 nM probe, 5 μL nuclease-free water (Gibco,
Life Technologies) and 0.125 μL Euroscript (Eurogen-
tec). The temperature profile was 30 min at 48 °C,
followed by 10 min at 95 °C and 45 cycles of 15 s at 95 °
C, followed by 1 min at 60 °C. The FCV RT-qPCR S2 [26]
reaction contained 0.5 μL Superscript III/RT Platinum Taq
Mix (Invitrogen, Life technologies), 300 nM forward pri-
mer, 900 nM reverse primer, 250 nM probe, 0.05 μL 2.5x
Rox dye, 0.625 μL 40 U/μL rRNasin® RNase Inhibitor (Pro-
mega, Dübendorf, Switzerland) or RNasin® Plus RNase In-
hibitor (Promega) and 3.95 μL nuclease-free water (Gibco,
Life Technologies). The temperature profile was 30 min at
50 °C, followed by 2 min at 95 °C and 45 cycles of 20 s at
95 °C, followed by 45 s at 60 °C. Each sample (TNA from
swab/cytobrush and TNA from cell culture supernatant) was
analyzed with both RT-qPCR assays (S1 and S2). All cats that
tested positive in at least one of the four RT-qPCR runs were
categorized as FCV-positive (FCV RT-qPCR S1 or RT-qPCR
S2 from swabs/cytobrush or from virus isolation).
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TNA from swab/cytobrush from each cat was also
tested for FHV-1 [43], C. felis [44], B. bronchiseptica [15]
and M. felis [45] by qPCR using previously described
methods. Moreover, the samples were also tested for
FeLV [46] and FIV viral RNA [47] by RT-qPCR because
both infections can lead to increased susceptibility to
other infections and can be associated with inflamma-
tory oral disease. Three samples from FCV-suspect cats
could not be analyzed for B. bronchiseptica, M. felis,
FeLV and FIV because of a lack of material.
Statistical analysis
Statistical analysis was performed utilizing the freely
available software program R version 3.2.0 [48]. Separ-
ately for the FCV-suspect and clinically healthy cats, de-
scriptive statistics with frequencies for male and female
cats, medians with 95 % confidence interval (CI) for age
and proportions of the dichotomous variables with 95 %
CI based on the binomial distribution are presented. Re-
gression models were applied to assess if the predictors
(age in years, sex: male or female, reproductive status:
intact or neutered, pedigree: yes or no, outdoor access,
living in groups of at least four cats, being vaccinated at
all or having received a primary immunization, having
received immunosuppressive, antimicrobial and/or anti-
viral treatment or being co-infected with M. felis, FHV-
1, C. felis and/or B. bronchiseptica) were significantly
associated with the outcome FCV infection. Univariable
regressions, with the outcome FCV were performed and
odds ratios with 95 % Wald confidence intervals are
shown. Due to the presence of missing values which re-
duced the number of complete cases (meaning cats with
information for all predictors) for FCV-suspect animals
to 168 and for clinically healthy animals to 88, missing
values were imputed with the package missForest [49],
separately for the FCV-suspect and clinically healthy
cats. Imputation was done iteratively based on a random
forest approach. Utilizing the imputed data sets, multi-
variable logistic regressions were performed with the
package MASS [50]. Models were built following two
different approaches. First, all variables with a p-value <
2 in univariable regression were considered in different
models, including interaction terms. Model selection
was based on AIC (Akaike’s information criterion) with
lower values of at least 2 considered indicative of a bet-
ter model fit. In case of between model differences
smaller than 2, the most parsimonious model was
chosen. Second, a stepwise regression approach in both
directions was applied including all variables, irrespect-
ive of their p-values in the univariate approach and
interaction terms. Diagnostic plots were assessed for the
robustness of the final models. Results are presented as
odds ratios and 95 % Wald confidence intervals. FCV
loads in swab/cytobrush samples were compared between
two groups using the Mann–Whitney U-test (pMWU) and
the Graph-Pad Prism Version 3.0 (GraphPad Software,
San Diego, CA, USA). Maps were produced using QGIS
Geographic Information System (v. 2.6.1) [51]. Canton
boundaries were provided by the Swiss Federal Office of
Topography.
Results
Summary statistics for all variables used in the statistical
analysis for FCV-suspect and healthy cats are presented
in Table 1. This includes the PCR results for URTD-
associated pathogens. FCV infection was detected in
45 % (95 % CI 38–52 %) of the FCV-suspect cats and in
8 % (95 % CI 4–15 %) of the healthy cats. Among the
200 FCV-suspect and 100 healthy cats, 40 % (95 % CI 33
– 47 %) and 14 % (95 % CI 8 – 22 %) respectively, were
co-infected with any of the tested URTD-associated
pathogens. In summary, among the co-infected FCV-
suspect cats, 77 % were positive for two, 21 % for three
and 3 % for four pathogens. Among the co-infected
healthy cats, 93 % were positive for two and 7 % for
three pathogens. For details see Additional file 1. In
26 % (95 % CI 20–33 %) of the FCV-suspect cats, none
of the tested URTD-associated pathogens were detected.
Five cats (four FCV-suspect and one healthy cat, 1.7 %,
95 % CI 0.4–5 %) tested positive either for FeLV or for
FIV. Because of the low prevalence, FIV and FeLV infec-
tions were not considered in the statistical analysis. Ap-
proximately two thirds of the cats lived in a group with
other cats (Table 1); details of the numbers of cats per
group and the frequency of FCV infection are shown in
Additional file 2. The majority of the FCV-suspect
(76 %, 95 % CI 69–82 %) and healthy cats (80 %, 95 %
CI 70–87 %) were vaccinated; of these 92 % of the FCV-
suspect (95 % CI 86–96 %) and the healthy cats (95 %
CI 83–97 %) had received a primary immunization de-
fined as a minimum of two vaccinations two to six
weeks apart with the same vaccine strain (Table 1). In
both groups of cats, the vaccine strain most frequently
used for primary immunization was FCV F9 (FCV-sus-
pect cats: 81 %, 95 % CI 73–88 %; healthy cats: 86 %,
95 % CI 75–93 %) followed by FCV G1/431 (FCV-sus-
pect cats: 10 %, 95 % CI 5–18 %; healthy cats: 11 %,
95 % CI 5–22 %). Because of the small number of cats
vaccinated with a vaccine strain other than F9, vaccine
strain was not considered in the statistical analysis.
Based on univariable regression models, in FCV-
suspect cats intact reproductive status, living in a group
of at least four cats, co-infection with M. felis and both
vaccination and primary immunization were found to be
significantly associated with FCV infection (Table 2).
The former three predictors were found to be risk fac-
tors by approximately doubling the chance of a FCV in-
fection (if being intact versus neutered, if living in a
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group of at least four cats and if being co-infected with
M. felis). Being vaccinated at all or having received a pri-
mary immunization were found to be protective factors
by reducing the chance of a FCV infection by approxi-
mately 50 %. In contrast, amongst the clinically healthy
cats, the vaccination predictors were not significantly as-
sociated with FCV infection (Table 2). Similarly to the
FCV-suspect cats, intact reproductive status and living
in a group of at least four cats were found to be risk fac-
tors, albeit with higher odds ratios and considerably lar-
ger confidence intervals than in the FCV-suspect cats.
Details on missing values, univariable regressions with
complete case and imputed data sets are presented in
Additional file 3. Whereas p-values obtained with the
original data and the imputed data are similar, p-values
from complete case analyses differ slightly.
Based on multivariable regression models, in FCV-
suspect animals only intact reproductive status, living in
a group of at least four cats and co-infection with M.
felis remained in the final model with all odds ratios be-
ing reduced by at least 10 % compared to the univariable
results (Table 3). Based on the stepwise regression with
all predictors, outdoor access was additionally found to
be a risk factor for FCV infection (data not shown).
None of the variables describing vaccination were found
to be significant in the multivariable models. Regarding
the clinically healthy cats, intact reproductive status and
living in a group of at least four cats remained in the
final model with higher odds ratios and larger confi-
dence intervals than in the FCV-suspect cats. Stepwise
regression was not possible for this group of cats due to
lack of convergence.
The clinical signs in the 200 cats chosen by the veter-
inary practitioners because of FCV-related symptoms are
shown in Table 4. In approximately half of the FCV-
suspect cats, gingivitis or classical signs of URTD, such
Table 1 Characteristics of the 200 FCV-suspect and the 100 healthy cats. The cats originated from 19 different cantons in
Switzerland
Parameter FCV-suspect cats (n = 200) Healthy cats (n = 100)
Median Lower 95 % CIa Upper 95 % CIa Median Lower 95 % CIa Upper 95 % CIa
Age (years) 4 0.20 16 0.75 0.3 14.8
Proportion Lower 95 % CIa Upper 95 % CIa Proportion Lower 95 % CIa Upper 95 % CIa
Sex (male) 0.60 0.52 0.66 0.61 0.51 0.71
Intact reproductive status 0.37 0.30 0.44 0.40 0.30 0.50
Pedigree 0.32 0.25 0.39 0.22 0.14 0.32
Breedbc
Maine Coon 0.09 0.05 0.14 0.02 0.01 0.07
British Shorthair 0.05 0.02 0.09 0.02 0.01 0.07
Norwegian Forest Cat 0.05 0.02 0.09 0.02 0.01 0.07
Persian 0.04 0.02 0.08 0.04 0.01 0.1
Siamese 0.03 0.01 0.06 0.02 0.01 0.07
Multi-cat household 0.72 0.65 0.78 0.63 0.53 0.72
Group housing with≥ 4 cats 0.22 0.16 0.29 0.16 0.09 0.25
Outdoor access 0.57 0.50 0.64 0.58 0.48 0.68
Contact with dog with kennel coughc 0.02 0 0.05 0.01 0 0.06
Vaccinated 0.76 0.69 0.82 0.80 0.70 0.87
Primary immunizationd 0.69 0.61 0.75 0.72 0.61 0.81
Immunosuppressive therapy 0.15 0.10 0.20 0.01 0.00 0.05
Antibiotic therapy 0.42 0.35 0.49 0.02 0.00 0.07
Antiviral therapy 0.05 0.02 0.08 0.00 0.00 0.04
FCV positivee 0.45 0.38 0.52 0.08 0.04 0.15
M. felis positivee 0.48 0.41 0.55 0.31 0.22 0.41
FHV-1 positivee 0.20 0.15 0.26 0.09 0.04 0.16
C. felis positivee 0.08 0.05 0.13 0.01 0.00 0.05
B. bronchiseptica positivee 0.04 0.02 0.08 0.02 0.00 0.07
aCI = Confidence interval. bOnly breeds with >5 cats in the study are listed. cDue to low numbers, these variables were not considered in the statistical analysis.
dPrimary immunization was defined as two subsequent vaccinations within 2 to 6 weeks with the same vaccine strain. ePositive by real-time qPCR/RT-qPCR
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as nasal discharge, ocular discharge, conjunctivitis and
sneezing were present. Approximately one third of the
cats exhibited stomatitis or caudal stomatitis, about 10 %
demonstrated oral or lingual ulceration and only a few
were found with swollen joints, lameness, skin ulcerations
or cutaneous edema. Gingivitis, stomatitis, caudal stoma-
titis, salivation and oral and lingual ulcerations were sig-
nificantly associated with FCV infection (Table 4). In
contrast, nasal and ocular discharge and sneezing were
significantly less common in the FCV PCR-positive than
in the FCV PCR-negative cats. When the FCV load in the
sample material was compared between FCV-positive dis-
eased and FCV-positive healthy cats, the FCV loads were
higher in the diseased cats, although statistical significance
was not reached (FCV S1 RT-qPCR; pMWU = 0.07; Fig. 2).
Discussion
The present study investigated FCV infection in 200 dis-
eased cats judged suspicious for FCV infection by private
veterinarians and in 100 clinically healthy cats, all sampled
in different regions of Switzerland. FCV infection was
detected in 45 % (95 % CI 38 – 52 %) of the cats with
FCV-related symptoms. This relatively low percentage of
PCR-positive symptomatic cats is in agreement with the
prevalence of FCV infection in cats in UK with respiratory
disease (33 %, 95 % CI 27–39 %) [19] and in cats in
Germany with chronic gingivostomatitis (54 %, 95 % CI
39–68 %) [5]. In the present study, cats were judged as
FCV-suspect by the veterinary practitioners based on writ-
ten instructions that listed FCV-related symptoms as de-
scribed in the literature [2, 40]. Interestingly, cats suffering
Table 2 Results of the univariable approach for the 200 FCV-suspect and the 100 healthy cats
Parameter FCV-suspect cats (n = 200) Healthy cats (n = 100)
p-value Odds ratio Lower 95 % CIa Upper 95 % CIa p-value Odds ratio Lower 95 % CIa Upper 95 % CIa
Age 0.12 0.70
Sex 0.38 0.51
Intact reproductive status 0.02 2.02 1.13 3.62 0.02 12.52 1.48 106.20
Pedigree 0.87 0.28
Multi-cat household 0.09 1.76 0.92 3.37 0.17
Group housing with≥ 4 cats 0.008 2.63 1.29 5.37 <0.001 26.33 4.61 150.42
Outdoor access 0.19 0.23
Vaccinated 0.03 0.48 0.24 0.94 0.57
Primary Immunizationb 0.03 0.49 0.26 0.92 0.83
Immunosuppressive therapy 0.40 1.00
Antibiotic therapy 0.26 0.99
Antivirale therapy 0.51 NAc
M. felis positived 0.02 2.03 1.15 3.59 0.06 4.23 0.94 18.99
FHV-1 positived 0.78 0.99
C. felis positived 0.27 0.99
B. bronchiseptica positived 0.74 0.99
Parameters significantly associated with FCV infection are shown in bold. Odds ratios and confidence intervals are given for p < 0.1
aCI = Confidence interval . bPrimary immunization was defined as two subsequent vaccinations within 2 to 6 weeks with the same vaccine strain. cNot applicable.
dPositive by real-time qPCR/RT-qPCR
Table 3 Results from multivariable regressions for the 200 FCV-suspect and the 100 healthy cats
Parametera FCV-suspect cats (n = 200) Healthy cats (n = 100)
Odds ratio Lower 95 % CIb Upper 95 % CIb Odds ratio Lower 95 % CIb Upper 95 % CIb
Intact reproductive status 1.80 0.99 3.28 22.22 1.85 266.73
Group housing with≥ 4 cats 2.11 1.02 4.34 46.39 5.70 377.72
M. felis positivec 1.75 0.97 3.14
Only parameters significantly associated with FCV infection are shown
aBased on the stepwise regression with all predictors, additionally outdoor access was found to be a risk factor for FCV infection. bCI = confidence interval.
cPositive by real-time qPCR
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from gingivitis and URTD-related symptoms were most
commonly selected by the veterinarians. However, only
gingivitis, stomatitis, caudal stomatitis, salivation and oral
and lingual ulcerations were significantly associated with
FCV infection but not the classical signs of URTD, such
as sneezing, nasal and ocular discharge. In contrast, sneez-
ing, nasal and ocular discharge were significantly less
common in the FCV-positive cats when compared to the
FCV-negative cats. This finding contrasts earlier studies
where FCV infection was significantly associated with fe-
line respiratory tract disease [14, 15, 19, 52]. However, in
accordance with our results, Bannasch and co-workers
found that among the five pathogens associated with
URTD examined (the same as in the present study), the
most important contributors to URTD were FHV-1,
Mycoplasma species and C. felis [16]. Acute FCV is known
to induce vesicular disease, which typically manifests as
oral and lingual ulcerations [53]. Ocular and nasal dis-
charge is only rarely reported after experimental FCV in-
fection [6, 36, 54]. Chronic FCV infection has been
strongly associated with the presence of gingivostomatitis
[5], although the exact pathogenesis of this disease is still
unknown. Our data suggest that for a clinical diagnosis of
FCV infection, the FCV-related symptoms should be
reconsidered and more stringently defined and the diag-
nosis confirmed by molecular testing.
It needs to be noted that the relatively low detection
rate of FCV in the FCV-suspect cats could also be attrib-
uted to a limited diagnostic sensitivity of the applied
diagnostic assays. In the current study, the criterion of
being FCV-positive was based on the presence of at least
one positive out of four real-time RT-qPCR runs (two
different PCR assays performed directly from the sample
material and after an enrichment step in cell culture).
This approach was chosen to maximize diagnostic sensi-
tivity. However, the remarkably high genetic variability of
FCV [55, 56] increases the likelihood of potential mis-
matches in the primer or probe binding sites, thus leading
to the possibility of failed real-time PCR amplification.
Interestingly, 26 % of the FCV-suspect cats tested
negative for all URTD-associated pathogens. Cats with a
non-infectious etiology for URTD (i.e., neoplasia, foreign
bodies or primary immune-mediated rhinitis) could ac-
count for some of these cases. Cats with non-infectious
URTD are clinically indistinguishable from cats with
URTD caused by infectious agents. Additionally, the de-
tection of the URTD-associated pathogens could have
failed due to sample degradation during the transport
from the veterinary practices to the laboratory [2]. To
avoid or minimize this effect, the samples in the present
study were analyzed within 96 h of collection. Finally,
the diagnostic sensitivity of the PCR assays could have
Table 4 Association of clinical signs with FCV infection in the 200 FCV-suspect cats
Clinical signs Number of
FCV-suspect cats
Number of
FCV-positive cats
Number of
FCV-negative cats
Odds ratios Lower
95 % CIa
Upper
95 % CIa
(n = 200) (n = 89) (n = 111)
Gingivitis 103 62 41 3.89 2.08 7.43
Stomatitis 59 43 16 5.50 2.71 11.64
Caudal stomatitis 61 40 21 3.48 1.78 6.95
Salivation 38 30 8 6.48 2.69 17.47
Oral ulceration 23 18 5 5.33 1.80 19.22
Lingual ulceration 20 15 5 4.27 1.40 15.67
Nasal discharge 112 38 74 0.37 0.20 0.69
Ocular discharge 102 34 68 0.39 0.21 0.72
Sneezing 84 27 57 0.41 0.22 0.77
Keratitis 10 3 7 0.52 0.08 2.36
Conjunctivitis 93 39 54 0.82 0.45 1.50
Anorexia 49 23 26 1.14 0.56 2.29
Apathy 47 21 26 1.01 0.49 2.05
Elevated body temperature 29 14 15 1.19 0.50 2.84
Lameness 7 5 2 3.23 0.51 34.67
Skin ulcerations 6 4 2 2.55 0.36 28.85
Joint swelling 2 2 0 6.37 0.30 134.5
Cutaneous edema 2 1 1 1.25 0.08 20.28
Significant associations are shown in bold
aCI = confidence interval
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been hampered by genetic alterations of the pathogens
within the target sequence of the applied PCR assays.
However, in contrast to RNA viruses such as FCV, a high
genetic variability is not necessarily expected for FHV-1,
C. felis, M. felis and B. bronchiseptica.
Approximately 8–9 % of the healthy cats in the
present study tested PCR-positive for FHV-1 and FCV.
This proportion is lower for FCV than reported in earl-
ier studies in the UK (22 %, 95 % CI 17–29 %) [19] and
in Germany (14 %, 95 % CI 6 – 27 %) [5]. As previously
reported [52], it is important to remember that some
cats, although clinically healthy, are shedders of infec-
tious pathogens related to URTD.
In the present study, risk factor analysis was per-
formed with univariable and multivariable regression
models. The latter were performed with imputed data
sets due to missing data. The selected multivariable re-
gression approach offers, in contrast to univariable
approaches, the possibility to adjust for confounding. In-
evitably however, it remains possible that not all relevant
confounders were recorded. Missing values leading sub-
sequently to different sample sizes of models with differ-
ent variables, preclude the possibility to compare the
model fit: thus data sets with imputed variables for the
missing values were generated. Although resulting p-
values obtained with the original and the imputed data
sets were similar in univariable analysis, any imputation
may potentially include bias. Two model-building ap-
proaches were performed for the FCV-suspect cats (the
stepwise approach was not possible for the clinically
healthy cats) to assure robustness of the final models.
Although found to be significant protective factors in
univariable models, statistical association for vaccination
status and primary immunization vanished in multivari-
able analysis. One reason might be that the predictors
“vaccination status” and “primary immunization” with
the categories “yes” and “no” (or “unknown” in 18 and 8
cases for the FCV-suspect and healthy cats respectively)
comprised a number of different vaccines, vaccinations
schemes and time elapsed since vaccination, thus, poten-
tially being too heterogeneous to actually show a statis-
tical association. In addition, FCV vaccines do not
induce sterilizing immunity, although they have been
shown to reduce the severity of clinical signs [30, 31].
Therefore, vaccine protection cannot be solely judged by
the PCR status of a cat. Furthermore, a cross-sectional
study is rather limited in assessing causal relationships,
especially since in a cross-sectional approach only preva-
lence can be estimated whereas incidence would be
more relevant.
An intact reproductive status, living in a group with at
least four cats and co-infection with M. felis were found
to be risk factors for FCV infection. All of these three
factors approximately doubled the chance of finding a
FCV infection. A number of interaction terms, including
interaction between groups of at least four cats and M.
felis infection or between vaccination and intact repro-
ductive status, were tested for potential association but
none was found to be statistically significant.
An association of FCV with intact reproductive status
has been reported in an earlier study [52]. Although no
clear explanation can be given for this association, pos-
sible reasons postulated earlier include hormonal effects,
which might alter the replication and the persistence of
the virus, and more social or aggressive interactions be-
tween the intact animals [52].
The association of FCV infection with housing in large
groups of cats was reported in previous studies [34, 57].
Cats kept in large groups are exposed to a higher infec-
tious pressure compared with cats living in smaller
groups. The high plasticity of the FCV genome and posi-
tive selection by the immune system support genomic
mutations and lead to a progressive evolution of FCV
variants in cat groups with cyclic reinfection of previ-
ously immune cats [58, 59]. In addition, strict quarantine
measures and excellent hygiene can be more challenging
to guarantee in large groups of cats, thereby favoring
FCV infections [15]. Breeders and other cat owners
should be educated about the benefits of housing cats in
small groups. A reduced group size does not only reduce
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Fig. 2 Comparison of FCV loads in the swab/cytobrush samples
from FCV-suspect cats and the healthy cats. Loads are given as CT
values from the real-time RT-qPCR S1 assay and are depicted as
boxplots. A low CT value corresponds to a high load. Of note, the
measurements are semi-quantitative because of the collection
procedure (cytobrushes and swabs)
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the risk of infection related to URTD in cats but also the
risk of other feline infections and the development of fe-
line infectious peritonitis [60, 61].
No clear explanation can be given for the association
of FCV infection with M. felis co-infection. Possible rea-
sons could be a similar transmission route, pathogenesis
or similar risk factors for infection. FCV and FHV-1 in-
fection have often been reported to occur concurrently,
and cats co-infected with FCV and FHV-1 had a high
risk of developing URTD [62]. However, no association
between FCV infection and co-infections with the other
tested pathogens FHV-1, C. felis and B. bronchiseptica
were found in the present study.
The different housing categories including private
home, farm, breeder, feral cat and cattery were recorded
in this study, but since the vast majority of cats was kept
in private homes, it was not possible to disentangle the
effect of different housing categories. The variable breed
was dichotomized into pedigree and non-pedigree cats
for statistical analysis because the number of cats per
breed was small. The absence of a statistical association
does therefore not preclude any potential association be-
tween specific breeds and FCV infection. For example
out of 17 FCV-suspect Maine Coons, 13 were found to
be FCV-infected and suffer from gingivostomatitis. It is
known that purebreds, such as the Maine Coons, are
predisposed to develop early or severe periodontal dis-
ease [63], but no association with FCV infection has
been described thus far. It should be noted however that
12 of the FCV-positive Main Coons were housed in
groups (data not shown).
In the present study, 76 % and 80 % of the FCV-
suspect and healthy cats, respectively, were vaccinated
against FCV and FHV-1 (i.e. had received some vaccina-
tions against FCV and FHV-1 at any time point). This
vaccination rate seems higher than the rate estimated for
Switzerland in 2009 according to the number of sold
vaccine doses (30 to 40 % of all Swiss cats vaccinated)
[64]. Thus, according to our numbers, the proportion of
vaccinated cats would be sufficiently high to provide
some protection for the population (herd immunity)
within the sampled population as opposed to protection
of the vaccinated host only [65]. However, the present
study is based on preselected populations of cats and
some of the cats had not received a proper primary
immunization or were lacking the necessary booster vac-
cinations, leaving some doubts about the actual level of
protection.
Conclusion
The present study assessed FCV infection in cats judged
FCV-suspect by veterinary practitioners and in clinically
healthy cats in Switzerland. FCV infection was detected
in less than half of the FCV-suspect cats. Within this
group of cats, infection was significantly associated with
gingivitis, stomatitis, caudal stomatitis, oral and lingual
ulcerations, but not with classical signs of URTD, such
as sneezing, nasal and ocular discharge. These results
suggest that the FCV-related symptoms should be critic-
ally reassessed and probably more stringently defined.
FCV infection was also detected in some healthy cats; this
observation underlines the importance of asymptomatic
shedders in FCV epidemiology. Housing in large groups
of cats was among the risk factors for FCV infection.
Thus, if problems with FCV are encountered in multi-cat
environments, reduction of group size in addition to the
generally recommended vaccination and quarantine mea-
sures for incoming and sick cats are advocated.
Additional files
Additional file 1: Number of cats PCR-positive for URTD-associated
pathogens and co-infections thereof. The 200 FCV-suspect and 100
healthy cats originated from 19 different cantons in Switzerland.
(PDF 7 kb)
Additional file 2: Frequency of FCV-positive and FCV-negative cats
according to number of cats housed per group. a) 200 FCV-suspect
cats; b) 100 healthy cats. FCV-pos./neg. = FCV-positive/negative in FCV
real-time RT-PCR. Number of cats = 1: single cats. The numbers in the
bars represent the absolute numbers of cats in the respective category.
(PDF 82 kb)
Additional file 3: Details on missing values, univariable regressions
with complete case and imputed data sets. (PDF 45 kb)
Abbreviations
B. bronchiseptica: Bordetella bronchiseptica; C. felis: Chlamydophila felis;
CI: confidence interval; FCV: Feline calicivirus; FeLV: Feline leukemia virus;
FHV-1: Feline herpesvirus-1; FIV: Feline immunodeficiency virus;
M. felis: Mycoplasma felis; qPCR: quantitative polymerase chain reaction;
RT-qPCR: reverse-transcriptase qPCR; TNA: total nucleic acid; URTD: upper
respiratory tract disease.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HL and RHL conceived the study. BW, FSB and RHL participated in the
design and coordination of the study. AB carried out the sample and data
collection and part of the laboratory work. BW and FSB were responsible for
clinical aspects of the study. MLM was responsible for all laboratory aspects.
RHL, SH, AD and AB performed the statistical analysis. BW, RHL and AB
drafted the manuscript. MLM, FSB, SH and HL edited the manuscript. All
authors read and approved the final manuscript.
Acknowledgements
The composition of the in-house produced viral transport medium was
kindly provided by the Diagnostic Department of the Institute of Medical
Virology, University of Zürich, Switzerland. The authors thank all participating
veterinarians for collecting the samples and case information, B. Weibel, T.
Meili , E. Goenczi and C. Asquith for excellent laboratory assistance and F.
Mavrot for providing the maps of the Swiss cantons. The laboratory work
was performed using the logistics of the Center for Clinical Studies,
Vetsuisse Faculty, University of Zurich. The study was partially funded by a
research grant from Merial, Lyon, France, and Biokema SA, Crissier-Lausanne,
Switzerland. This study was the doctoral thesis of A. Berger.
Berger et al. BMC Veterinary Research  (2015) 11:282 Page 10 of 12
Author details
1Clinical Laboratory, Vetsuisse Faculty, University of Zurich, Zurich,
Switzerland. 2Clinic for Small Animal Internal Medicine, Vetsuisse Faculty,
University of Zurich, Zurich, Switzerland. 3Center for Clinical Studies, Vetsuisse
Faculty, University of Zurich, Zurich, Switzerland. 4Section of Epidemiology,
Vetsuisse Faculty, University of Zurich, Zurich, Switzerland. 5Present address:
Clinical Laboratory, Vetsuisse Faculty, University of Zurich, Winterthurerstr.
260, 8057 Zurich, Switzerland.
Received: 7 February 2015 Accepted: 9 November 2015
References
1. Harrison TM, Sikarskie J, Kruger J, Wise A, Mullaney TP, Kiupel M, et al.
Systemic calicivirus epidemic in captive exotic felids. J Zoo Wildl Med.
2007;38(2):292–9.
2. Radford AD, Addie D, Belak S, Boucraut-Baralon C, Egberink H, Frymus T, et al.
Feline calicivirus infection. ABCD guidelines on prevention and management.
J Feline Med Surg. 2009;11(7):556–64. doi:10.1016/j.jfms.2009.05.004.
3. Reubel GH, Hoffmann DE, Pedersen NC. Acute and chronic faucitis of
domestic cats. A feline calicivirus-induced disease. Vet Clin North Am Small
Anim Pract. 1992;22(6):1347–60.
4. Wardley RC, Povey RC. The pathology and sites of persistence associated
with three different strains of feline calicivirus. Res Vet Sci. 1977;23(1):15–9.
5. Belgard S, Truyen U, Thibault JC, Sauter-Louis C, Hartmann K. Relevance of
feline calicivirus, feline immunodeficiency virus, feline leukemia virus, feline
herpesvirus and Bartonella henselae in cats with chronic gingivostomatitis.
Berl Munch Tierarztl Wochenschr. 2010;123(9–10):369–76.
6. TerWee J, Lauritzen AY, Sabara M, Dreier KJ, Kokjohn K. Comparison of the
primary signs induced by experimental exposure to either a pneumotrophic
or a ‘limping’ strain of feline calicivirus. Vet Microbiol. 1997;56(1–2):33–45.
doi:10.1016/S0378-1135(96)01344-2.
7. Dawson S, Bennett D, Carter SD, Bennett M, Meanger J, Turner PC, et al.
Acute arthritis of cats associated with feline calicivirus infection. Res Vet Sci.
1994;56(2):133–43.
8. Levy JK, Marsh A. Isolation of calicivirus from the joint of a kitten with
arthritis. J Am Veterinary Medical Assoc. 1992;201(5):753–5.
9. Pedersen NC, Elliott JB, Glasgow A, Poland A, Keel K. An isolated epizootic
of hemorrhagic-like fever in cats caused by a novel and highly virulent
strain of feline calicivirus. Vet Microbiol. 2000;73(4):281–300.
10. Schorr-Evans EM, Poland A, Johnson WE, Pedersen NC. An epizootic of
highly virulent feline calicivirus disease in a hospital setting in New England.
J Feline Med Surg. 2003;5(4):217–26.
11. Coyne KP, Jones BR, Kipar A, Chantrey J, Porter CJ, Barber PJ, et al. Lethal
outbreak of disease associated with feline calicivirus infection in cats. Vet
Rec. 2006;158(16):544–50.
12. Reynolds BS, Poulet H, Pingret JL, Jas D, Brunet S, Lemeter C, et al. A
nosocomial outbreak of feline calicivirus associated virulent systemic disease
in France. J Feline Med Surg. 2009;11(8):633–44. doi:10.1016/j.jfms.2008.12.005.
13. Schulz BS, Hartmann K, Unterer S, Eichhorn W, Majzoub M, Homeier-Bachmann
T, et al. Two outbreaks of virulent systemic feline calicivirus infection in cats in
Germany. Berl Munch Tierarztl Wochenschr. 2011;124(5–6):186–93.
14. Cai Y, Fukushi H, Koyasu S, Kuroda E, Yamaguchi T, Hirai K. An etiological
investigation of domestic cats with conjunctivitis and upper respiratory tract
disease in Japan. J Vet Med Sci. 2002;64(3):215–9.
15. Helps CR, Lait P, Damhuis A, Bjornehammar U, Bolta D, Brovida C, et al.
Factors associated with upper respiratory tract disease caused by feline
herpesvirus, feline calicivirus, Chlamydophila felis and Bordetella
bronchiseptica in cats: experience from 218 European catteries. Vet Rec.
2005;156(21):669–73.
16. Bannasch MJ, Foley JE. Epidemiologic evaluation of multiple respiratory
pathogens in cats in animal shelters. J Feline Med Surg. 2005;7(2):109–19.
doi:10.1016/j.jfms.2004.07.004.
17. Hoover EA, Kahn DE. Experimentally induced feline calicivirus infection:
clinical signs and lesions. J Am Veterinary Medical Assoc. 1975;166(5):463–8.
18. Harbour DA, Howard PE, Gaskell RM. Isolation of feline calicivirus and feline
herpesvirus from domestic cats 1980 to 1989. Vet Rec. 1991;128(4):77–80.
19. Binns SH, Dawson S, Speakman AJ, Cuevas LE, Hart CA, Gaskell CJ, et al. A
study of feline upper respiratory tract disease with reference to prevalence
and risk factors for infection with feline calicivirus and feline herpesvirus.
J Feline Med Surg. 2000;2(3):123–33. doi:10.1053/jfms.2000.0084.
20. Foster SF, Barrs VR, Martin P, Malik R. Pneumonia associated with
Mycoplasma spp in three cats. Aust Vet J. 1998;76(7):460–4.
21. Foley JE, Rand C, Bannasch MJ, Norris CR, Milan J. Molecular epidemiology
of feline bordetellosis in two animal shelters in California. USA Prev Vet
Med. 2002;54(2):141–56.
22. Hartmann A, Hartmann K. Treatment and management of Chlamydophila
felis infections in cats. Tierarztl Prax Ausg K Kleintiere Heimtiere.
2010;38(4):217–26.
23. Masubuchi K, Nosaka H, Iwamoto K, Kokubu T, Yamanaka M, Shimizu Y.
Experimental infection of cats with Chlamydophila felis. J Vet Med Sci.
2002;64(12):1165–8.
24. McArdle HC, Dawson S, Coutts AJ, Bennett M, Hart CA, Ryvar R, et al.
Seroprevalence and isolation rate of Bordetella bronchiseptica in cats in the
UK. Vet Rec. 1994;135(21):506–7.
25. Helps C, Lait P, Tasker S, Harbour D. Melting curve analysis of feline
calicivirus isolates detected by real-time reverse transcription PCR. J Virol
Methods. 2002;106(2):241–4.
26. Abd-Eldaim MM, Wilkes RP, Thomas KV, Kennedy MA. Development and
validation of a TaqMan real-time reverse transcription-PCR for rapid
detection of feline calicivirus. Arch Virol. 2009;154(4):555–60. doi:10.1007/
s00705-009-0337-5.
27. Sykes JE, Studdert VP, Browning GF. Detection and strain differentiation of
feline calicivirus in conjunctival swabs by RT-PCR of the hypervariable
region of the capsid protein gene. Arch Virol. 1998;143(7):1321–34.
28. Marsilio F, Di Martino B, Decaro N, Buonavoglia C. A novel nested PCR for the
diagnosis of calicivirus infections in the cat. Vet Microbiol. 2005;105(1):1–7.
doi:10.1016/j.vetmic.2004.09.017.
29. Wilhelm S, Truyen U. Real-time reverse transcription polymerase chain
reaction assay to detect a broad range of feline calicivirus isolates. J Virol
Methods. 2006;133(1):105–8. doi:10.1016/j.jviromet.2005.10.011.
30. Orr CM, Gaskell CJ, Gaskell RM. Interaction of a combined feline viral
rhinotracheitis-feline calicivirus vaccine and the FVR carrier state. Vet Rec.
1978;103(10):200–2.
31. Bittle JL, Rubic WJ. Immunization against feline calicivirus infection. Am J
Vet Res. 1976;37(3):275–8.
32. Radford AD, Dawson S, Coyne KP, Porter CJ, Gaskell RM. The challenge for
the next generation of feline calicivirus vaccines. Vet Microbiol. 2006;117(1):
14–8. doi:10.1016/j.vetmic.2006.04.004.
33. Lauritzen A, Jarrett O, Sabara M. Serological analysis of feline calicivirus
isolates from the United States and United Kingdom. Vet Microbiol.
1997;56(1–2):55–63. doi:10.1016/S0378-1135(96)01252-7.
34. Porter CJ, Radford AD, Gaskell RM, Ryvar R, Coyne KP, Pinchbeck GL, et al.
Comparison of the ability of feline calicivirus (FCV) vaccines to neutralise a
panel of current UK FCV isolates. J Feline Med Surg. 2008;10(1):32–40. doi:10.
1016/j.jfms.2007.06.011.
35. Addie D, Poulet H, Golder MC, McDonald M, Brunet S, Thibault JC, et al.
Ability of antibodies to two new caliciviral vaccine strains to neutralise
feline calicivirus isolates from the UK. Vet Rec. 2008;163(12):355–7.
36. Poulet H, Brunet S, Leroy V, Chappuis G. Immunisation with a combination
of two complementary feline calicivirus strains induces a broad cross-
protection against heterologous challenges. Vet Microbiol. 2005;106(1–2):
17–31. doi:10.1016/j.vetmic.2004.12.010.
37. Huang C, Hess J, Gill M, Hustead D. A dual-strain feline calicivirus vaccine
stimulates broader cross-neutralization antibodies than a single-strain
vaccine and lessens clinical signs in vaccinated cats when challenged with
a homologous feline calicivirus strain associated with virulent systemic
disease. J Feline Med Surg. 2010;12(2):129–37. doi:10.1016/j.jfms.2009.08.006.
38. Masubuchi K, Wakatsuki A, Iwamoto K, Takahashi T, Kokubu T, Shimizu M.
Immunological and genetic characterization of feline caliciviruses used in
the development of a new trivalent inactivated vaccine in Japan. J Veterinary
Medical Science. 2010;72(9):1189–94.
39. Schweizerische Eidgenossenschaft: Schweizer Tierschutzgesetzt (TSchG).
2008. https://www.admin.ch/opc/de/classified-compilation/20022103/index.
html. Accessed 18 August 2015.
40. Gerriets W, Joy N, Huebner-Guthardt J, Eule JC. Feline calicivirus: a
neglected cause of feline ocular surface infections? Vet Ophthalmol. 2012;
15(3):172–9. doi:10.1111/j.1463-5224.2011.00957.x.
41. Willi B, Boretti FS, Baumgartner C, Tasker S, Wenger B, Cattori V, et al.
Prevalence, risk factor analysis, and follow-up of infections caused by three
feline hemoplasma species in cats in Switzerland. J Clinical Microbiology.
2006;44(3):961–9. doi:10.1128/JCM.44.3.961-969.2006.
Berger et al. BMC Veterinary Research  (2015) 11:282 Page 11 of 12
42. Lutz H, Lehmann R, Winkler G, Kottwitz B, Dittmer A, Wolfensberger C, et al.
Feline immunodeficiency virus in Switzerland: clinical aspects and
epidemiology in comparison with feline leukemia virus and coronaviruses.
Schweiz Arch Tierheilkd. 1990;132(5):217–25.
43. Vogtlin A, Fraefel C, Albini S, Leutenegger CM, Schraner E, Spiess B, et al.
Quantification of feline herpesvirus 1 DNA in ocular fluid samples of
clinically diseased cats by real-time TaqMan PCR. J Clinical Microbiology.
2002;40(2):519–23.
44. Helps C, Reeves N, Egan K, Howard P, Harbour D. Detection of
Chlamydophila felis and feline herpesvirus by multiplex real-time PCR
analysis. J Clinical Microbiology. 2003;41(6):2734–6.
45. Soderlund R, Bolske G, Holst BS, Aspan A. Development and evaluation of a
real-time polymerase chain reaction method for the detection of
Mycoplasma felis. J Vet Diagn Invest. 2011;23(5):890–3. doi:10.1177/
1040638711407479.
46. Tandon R, Cattori V, Gomes-Keller MA, Meli ML, Golder MC, Lutz H, et al.
Quantitation of feline leukaemia virus viral and proviral loads by TaqMan
real-time polymerase chain reaction. J Virol Methods. 2005;130(1–2):124–32.
doi:10.1016/j.jviromet.2005.06.017.
47. Klein D, Leutenegger CM, Bahula C, Gold P, Hofmann-Lehmann R, Salmons
B, et al. Influence of preassay and sequence variations on viral load
determination by a multiplex real-time reverse transcriptase-polymerase
chain reaction for feline immunodeficiency virus. J Acquired Immune
Deficiency Syndromes. 2001;26(1):8–20.
48. R-Core-Team. A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria. 2015. http://www.R-
project.org. Accessed 11 July 2015 .
49. Stekhoven D, Buehlmann P. MissForest - non-parametric missing value
imputation for mixed-type data. Bioinformatics. 2012;28:112–8.
50. Venables W, Ripley B. Modern Applied Statistics with S. 4th ed. New York:
Springer; 2002.
51. QGIS Development Team. QGIS Geographic Information System. Open
Source Geospatial Foundation Project. Brighton. 2014. http://qgis.osgeo.org.
Accessed 18 August 2015.
52. Wardley RC, Gaskell RM, Povey RC. Feline respiratory viruses–their
prevalence in clinically healthy cats. J Small Anim Pract. 1974;15(9):579–86.
53. Pesavento PA, Chang KO, Parker JS. Molecular virology of feline calicivirus.
Vet Clin North Am Small Anim Pract. 2008;38(4):775–86. doi:10.1016/j.cvsm.
2008.03.002. vii.
54. Lesbros C, Martin V, Najbar W, Sanquer A, McGahie D, Eun HM, et al.
Protective efficacy of the calicivirus valency of the leucofeligen vaccine
against a virulent heterologous challenge in kittens. Vet Med Int. 2013;2013:
232397. doi:10.1155/2013/232397.
55. Coyne KP, Christley RM, Pybus OG, Dawson S, Gaskell RM, Radford AD.
Large-scale spatial and temporal genetic diversity of feline calicivirus. J Virol.
2012;86(20):11356–67. doi:10.1128/JVI.00701-12.
56. Radford AD, Dawson S, Ryvar R, Coyne K, Johnson DR, Cox MB, et al. High
genetic diversity of the immunodominant region of the feline calicivirus
capsid gene in endemically infected cat colonies. Virus Genes.
2003;27(2):145–55.
57. Zicola A, Saegerman C, Quatpers D, Viandier J, Thiry E. Feline herpesvirus 1
and feline calicivirus infections in a heterogeneous cat population of a
rescue shelter. J Feline Med Surg. 2009;11(12):1023–7. doi:10.1016/j.jfms.
2009.05.023.
58. Radford AD, Turner PC, Bennett M, McArdle F, Dawson S, Glenn MA, et al.
Quasispecies evolution of a hypervariable region of the feline calicivirus
capsid gene in cell culture and in persistently infected cats. J Gen Virol.
1998;79(Pt 1):1–10.
59. Coyne KP, Edwards D, Radford AD, Cripps P, Jones D, Wood JL, et al.
Longitudinal molecular epidemiological analysis of feline calicivirus infection
in an animal shelter: a model for investigating calicivirus transmission within
high-density, high-turnover populations. J Clinical Microbiology.
2007;45(10):3239–44. doi:10.1128/JCM.01226-07.
60. Addie D, Belak S, Boucraut-Baralon C, Egberink H, Frymus T, Gruffydd-Jones
T, et al. Feline infectious peritonitis. ABCD guidelines on prevention and
management. J Feline Med Surg. 2009;11(7):594–604. doi:10.1016/j.jfms.
2009.05.008.
61. Foley JE, Poland A, Carlson J, Pedersen NC. Risk factors for feline infectious
peritonitis among cats in multiple-cat environments with endemic feline
enteric coronavirus. J Am Veterinary Medical Assoc. 1997;210(9):1313–8.
62. Gaskell CJ, Radford A, Dawson S. Feline infectious respiratory disease. In:
Chandler EA, Gaskell CJ, Gaskell RM, editors. Feline Medicine and
Therapeutics. 3rd ed. Oxford: Blackwell Publishing; 2004. p. 577–95.
63. Girard N, Servet E, Biourge V, Hennet P. Periodontal health status in a
colony of 109 cats. J Vet Dent. 2009;26(3):147–55.
64. Gesellschaft Schweizerischer Tierärztinnen und Tierärzte GST, Schweizerische
Vereinigung für Kleintiermedizin (SVK). Geliebt! Geimpft? Gesunde Tiere
machen Freude. http://www.gstsvs.ch/de/themen-standpunkte/aktuelle-
meldungen/news-search/newsdetail/article/2009/04/30/title/geliebt-gei.
html. Accessed 5 February 2015.
65. Horzinek MC, Thiry E. Vaccines and vaccination: the principles and the
polemics. J Feline Med Surg. 2009;11(7):530–7. doi:10.1016/j.jfms.2009.05.012.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Berger et al. BMC Veterinary Research  (2015) 11:282 Page 12 of 12
